Home › Research › Cognitive tests and assessment
Associations of plasma von Willebrand Factor levels with cognitive decline and neurodegeneration in older adults without dementia
Pan Fu, Meiling Hu. Frontiers in Aging Neuroscience, 2025-09-03
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Previous studies have suggested that von Willebrand Factor (VWF) may be implicated in the pathogenesis of Alzheimer’s disease (AD). However, the association between plasma VWF levels and cognitive decline and neurodegeneration in older adults without dementia remains unclear. Methods We investigated the cross-sectional and longitudinal associations between plasma von Willebrand Factor (VWF) levels and cognitive decline, as measured by the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), as well as the volumes of six brain regions: the hippocampus, entorhinal cortex, middle temporal gyrus, fusiform gyrus, ventricles, and whole brain. Linear mixed-effects models were used to assess the association between plasma VWF levels and longitudinal changes in cognitive function and neuroimaging markers over time. Results The study cohort consisted of 340 older adults without dementia at baseline. We observed that lower plasma VWF levels were associated with a faster rate of cognitive decline (MMSE: coefficient = 0.204, 95% CIs = [0.030, 0.378], p-value = 0.021; CDR-SB: coefficient = −0.268, 95% CIs = [−0.374, −0.163], p-value 0.05). Conclusion Our findings may contribute to the growing body of knowledge on the vascular contributions to cognitive function and may help identify potential biomarkers for the early detection and intervention of AD.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study. In older adults without dementia, lower plasma von Willebrand Factor levels were linked to a faster rate of cognitive decline over time. This may help identify a potential biomarker for early detection, but it does not test any treatment or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fu, P., & Hu, M. (2025). Associations of plasma von Willebrand Factor levels with cognitive decline and neurodegeneration in older adults without dementia. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2025.1595071
Vancouver
Fu P, Hu M. Associations of plasma von Willebrand Factor levels with cognitive decline and neurodegeneration in older adults without dementia. Frontiers in Aging Neuroscience. 2025. doi:10.3389/fnagi.2025.1595071. PMID: 40969184.
BibTeX
@article{fu2025-40969184,
author = {Fu, Pan and Hu, Meiling},
title = {{Associations of plasma von Willebrand Factor levels with cognitive decline and neurodegeneration in older adults without dementia}},
journal = {Frontiers in Aging Neuroscience},
year = {2025},
doi = {10.3389/fnagi.2025.1595071},
pmid = {40969184},
url = {https://doi.org/10.3389/fnagi.2025.1595071}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Background Previous studies have suggested that von Willebrand Factor (VWF) may be implicated in the pathogenesis of Alzheimer’s disease (AD).
- Results The study cohort consisted of 340 older adults without dementia at baseline.
- We observed that lower plasma VWF levels were associated with a faster rate of cognitive decline (MMSE: coefficient = 0.204, 95% CIs = [0.030, 0.378], p-value = 0.021; CDR-SB: coefficient = −0.268, 95% CIs = [−0.374, −0.163], p-value 0.05).
- Conclusion Our findings may contribute to the growing body of knowledge on the vascular contributions to cognitive function and may help identify potential biomarkers for the early detection and intervention of AD.
Why it matters
In older adults without dementia, lower plasma von Willebrand Factor levels were linked to a faster rate of cognitive decline over time. This may help identify a potential biomarker for early detection, but it does not test any treatment or prevention.
Study details
- Study designcross-sectional
- Evidence strengthModerate
How this study scored 39/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 37 of the 96 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Aging Neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Meiling Hu holds only 6 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Taizhou First People's Hospital: institution h-index 95 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40969184) |
| Free to read | 2 / 2 | Free to read |
| Points | 37 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 37 of the 96 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2025.1595071
- PubMed: 40969184
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.